ReviewCancer treatment reviews2017
Immunologic approaches for the treatment of multiple myeloma.
Review in Cancer treatment reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.British journal of haematology · 2020Trial
- Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma.Scientific reports · 2018Trial
- Recent advances in targeted drug delivery systems for multiple myeloma.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.CPT: pharmacometrics & systems pharmacology · 2023Article
- Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.OncoTargets and therapy · 2023Review
- BCMA in Multiple Myeloma-A Promising Key to Therapy.Journal of clinical medicine · 2021Review
- Successful recovery of a patient with multiple myeloma from severe coronavirus disease 2019 (COVID-19) pneumonia during the first chemotherapy cycle: A case report.Experimental and therapeutic medicine · 2021Article
- Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma.Frontiers in immunology · 2021Article
- HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma.Frontiers in oncology · 2021Article
- Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.JCI insight · 2019Article
- [Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].Der Internist · 2019Article
- CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies.The AAPS journal · 2019Review
- Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.Annals of hematology · 2019Review
- The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.International journal of molecular sciences · 2019Review
- Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients.Frontiers in immunology · 2019Article
- Immunotherapy in myeloma: how far have we come?Therapeutic advances in hematology · 2019Review
- CARs and other T cell therapies for MM: The clinical experience.Best practice & research. Clinical haematology · 2018Review
- Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance.Clinical & translational immunology · 2018Review
- [Multiple myeloma : What has been confirmed in therapy?]Der Internist · 2017Review
- CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.American journal of cancer research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The FDA approval of two monoclonal antibodies in 2015has heralded a new era of targeted immunotherapies for multiple myeloma (MM). In this review we discuss the recent approaches using different immunological components to treat MM. In particular, we review current monoclonal antibody based therapies, engineered T- and NK cell products, 'off-target' immunomodulation, and strategies utilizing allogeneic cell transplantation in MM. We discuss how an immunologic approach offers promise for the treatment of this genetically heterogeneous disease, and how patients with acquired drug resistance may particularly benefit from these therapies. We also describe some of the limitations of the current strategies and speculate on the future of personalized immunotherapies for MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.